-
Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial. Oncotarget 11: 2906-2908, 2020
Oshima T, Yoshikawa T (corresponding author), Miyagi Y, Morita S, Yamamoto M, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, Yokose T, Hiroshima Y, Aoyama T, Hayashi T, Ogata T, Cho H, Rino Y, Masuda M, Tsuburaya A, Sakamoto J.
-
Intraoperative blood loss as an independent prognostic factor for curative resection after neoadjuvant chemotherapy for gastric cancer: a single-center retrospective cohort study. Surg Today. 2020 Aug 24. doi: 10.1007/s00595-020-02114-3. Online ahead of print. Surg Today. 2020. PMID: 32839832
Hayashi M, Yoshikawa T (corresponding author), Yura M, Otsuki S, Yamagata Y, Morita S, Katai H, Nishida T.
-
Predictive value of the surgical Apgar score on postoperative complications in advanced gastric cancer patients treated with neoadjuvant chemotherapy followed by radical gastrectomy: a single-center retrospective study. BMC Surg. 2020 Jul 11;20(1):150. doi: 10.1186/s12893-020-00813-9.BMC Surg. 2020. PMID: 32652977
Hayashi M, Yoshikawa T (corresponding author), Yura M, Otsuki S, Yamagata Y, Morita S, Katai H, Nishida T.
-
Is splenectomy for dissecting splenic hilar lymph nodes justified for scirrhous gastric cancer? Gastric Cancer 2020 Mar 24.
Hayashi T, Yoshikawa T (equally contributed, corresponding author), Kamiya A, Date K, Wada T, Otsuki S, Yamagata Y, Katai H, Nishida T.
-
A Nodal Diagnosis by Computed Tomography Is Unreliable for Patients Who Need Additional Gastrectomy After Endoscopic Submucosal Dissection. Surgery Today 2020 Mar 4.
Wada T, Yoshikawa T (corresponding author), Kamiya A, Date K, Hayashi T, Otsuki S, Yamagata Y, Katai H, Nishida T.
-
Comprehensive biomarker analyses identifies HER2, EGFR, MET RNA expression and thymidylate synthase 5'UTR SNP as predictors of benefit from S-1 adjuvant chemotherapy in Japanese patients with stage II/III gastric cancer. J Cancer; 10(21):5130-5138, 2019
Yoshikawa T, Aoyama T, Sakamaki K, Oshima T, Lin J, Zhang S, Sapari NS, Soong R, Tan I, Chan XB, Bottomley D, Hewitt LC, Arai T, Teh BT, Epstein D, Ogata T, Kameda Y, Miyagi Y, Tsuburaya A, Morita S, Grabsch HI, Tan P.
-
Is surgery alone sufficient for treating T1 gastric cancer with extensive lymph node metastases? Gastric Cancer 23(2); 349-355, 2020.
Yura M, Yoshikawa T (corresponding author), Otsuki S, Yamagata Y, Morita S, Katai H, Nishida T.
-
ASO Author Reflections: Splenic Hilar Nodal Dissection for Proximal Advanced Gastric Cancer. Ann Surg Oncol 26: S588-S589, 2019.
Yura M, Yoshikawa T (corresponding author).
-
Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial. JAMA Netw Open. 2019 Aug 2;2(8):e198243. doi: 10.1001/jamanetworkopen.2019.8243.
Yoshikawa T, Muro K, Shitara K, Oh DY, Kang YK, Chung HC, Kudo T, Chin K, Kadowaki S, Hamamoto Y, Hironaka S, Yoshida K, Yen CJ, Omuro Y, Bai LY, Maeda K, Ozeki A, Yoshikawa R, Kitagawa Y.
-
Different risks of nodal metastasis by tumor location in remnant gastric cancer after curative gastrectomy for gastric cancer. Gastric Cancer 23(1); 195-201, Jan 2020. 2019 Jul 13. doi: 10.1007/s10120-019-00989-x. [Epub ahead of print]
Takahashi K, Yoshikawa T (corresponding author), Morita S, Kinoshita T, Yura M, Otsuki S, Tokunaga M, Yamagata Y, Kaito A, Katai H.
-
Does neoadjuvant chemotherapy cancel out the negative survival impact induced by surgical complications after gastrectomy? Gastric Cancer. 2019 Nov;22(6):1274-1284. doi: 10.1007/s10120-019-00957-5. Epub 2019 Apr 3.
Hayashi M, Yoshikawa T (corresponding author), Yura M, Otsuki S, Yamagata Y, Morita S, Katai H, Nishida T.
-
Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer. Gastric Cancer. 2019 Sep;22(5):1029-1035. doi: 10.1007/s10120-019-00938-8. Epub 2019 Feb 18.
Yura M, Yoshikawa T (corresponding author), Otsuki S, Yamagata Y, Morita S, Katai H, Nishida T.
-
Current status of the “enhanced recovery after surgery” program in gastric cancer surgery. Ann Gastroenterol Surg. 2019 Jan 21;3(3):231-238. doi: 10.1002/ags3.12232. eCollection 2019 May.
Yamagawa Y, Yoshikawa T (corresponding author) , Yura M, Otsuki S, Yamagata Y, Morita S, Katai H, Nishida T.
-
Effects of perioperative Eicosapentaenoic acid-enriched oral nutritional supplement on lean body mass after total gastrectomy for gastric cancer. J Cancer. 2019 Jan 29;10(5):1070-1076. doi: 10.7150/jca.29632. eCollection 2019.
Aoyama T, Yoshikawa T (corresponding author) , Ida S, Cho H, Sakamaki K, Ito Y, Fujitani K, Takiguchi N, Kawashima Y, Nishikawa K, Oshima T, Nunobe S, Hiki N.
-
Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. Lancet Gastroenterol Hepatol. 2019 Mar;4(3):208-216. doi: 10.1016/S2468-1253(18)30383-2. Epub 2019 Jan 22.
Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, Kaji M, Fukushima N, Hato S, Choda Y, Yabusaki H, Yoshida K, Ito S, Takeno A, Yasuda T, Kawachi Y, Katayama H, Fukuda H, Boku N, Sano T, Sasako M.
-
The Therapeutic Survival Benefit of Splenic Hilar Nodal Dissection for Advanced Proximal Gastric Cancer Invading the Greater Curvature. Ann Surg Oncol. 2019 Mar;26(3):829-835. doi: 10.1245/s10434-018-07122-9. Epub 2018 Dec 19.
Yura M, Yoshikawa T (corresponding author), Otsuki S, Yamagata Y, Morita S, Katai H, Nishida T.
-
Equivalent feasibility and safety of perioperative care by ERAS in open and laparoscopy-assisted distal gastrectomy for gastric cancer: a single-institution ancillary study using the patient cohort enrolled in the JCOG0912 phase III trial. Gastric Cancer. 2019 May;22(3):617-623. doi: 10.1007/s10120-018-0873-3. Epub 2018 Sep 7.
Aoyama T, Yoshikawa T (corresponding author), Sato T, Hayashi T, Yamada T, Ogata T, Cho H.
-
Identification of a high-risk subtype of intestinal-type Japanese gastric cancer by quantitative measurement of the luminal tumor proportion. Cancer Med. 2018 Oct;7(10):4914-4923. doi: 10.1002/cam4.1744. Epub 2018 Aug 29.
Aoyama T, Hutchins G, Arai T, Sakamaki K, Miyagi Y, Tsuburaya A, Ogata T, Oshima T, Earle S, Yoshikawa T, Grabsch HI.
-
Priority of lymph node dissection for proximal gastric cancer invading the greater curvature. Gastric Cancer. 2018 May;21(3):569-572. doi: 10.1007/s10120-017-0775-9. Epub 2017 Nov 8.
Maezawa Y, Aoyama T, Yamada T, Kano K, Hayashi T, Sato T, Oshima T, Rino Y, Masuda M, Ogata T, Cho H, Yoshikawa T (corresponding author).
-
The Negative Survival Impact of Infectious Complications After Surgery is Canceled Out by the Response of Neoadjuvant Chemotherapy in Patients with Esophageal Cancer. Ann Surg Oncol. 2018 Jul;25(7):2034-2043.
Kano K, Aoyama T, Yoshikawa T (corresponding author), Maezawa Y, Nakajima T, Hayashi T, Yamada T, Sato T, Oshima T, Rino Y, Masuda M, Cho H, Ogata T.
-
吉川貴己．がんの進行度とRECISTによる治療効果判定．消化器外科専門医の心得、日本消化器外科学会（編）、pp128-131、杏林舎、東京、2020
-
吉川貴己．胃がんに対する術後補助化学療法の選択．うまく続ける消化器がん薬物療法の基本とコツ、加藤 健/森実千種（編）、pp81-91、羊土社、東京、2016
-
吉川貴己、尾形高士、長 晴彦．LECSの未来像－外科の立場から．LECS イラストと写真で見る内視鏡医と外科医のコラボレーション手術、腹腔鏡・内視鏡合同手術研究会（編）、170-171、メジカルレビュー社、東京、2015
-
吉川貴己．スキルス胃がんの治療．インフォームドコンセントのための図説シリーズ 胃がん、笹子三津留（編）、pp76-81、医薬ジャーナル、大阪/東京、2012
-
吉川貴己．胃がんに対する術後補助化学療法の実際(S-1単独療法)．うまく続ける消化管がん化学療法、滝内比呂也（編）、pp71-79、羊土社、東京、2011
-
吉川貴己、円谷 彰．消化器癌化学療法と腫瘍学．オンコロジークリニカルガイド 消化器癌化学療法 食道・胃・大腸、久保田哲郎→瀧内比呂也、大村健二（編）、pp2-13、南山堂、東京、2007(初版)、2009(第2版)、2011(第3版)
-
吉川貴己．がん患者における栄養管理のエッセンス 栄養不足になるのはどうして？～がんの時間学と栄養障害 がん患者の栄養管理、大村健二（編）、pp55-67、南山堂、東京、2009
-
吉川貴己．胃癌補助化学療法の現状と展望 胃外科の要点と盲点、荒井邦佳（編）、pp142-143、文光堂、東京、2009(第2版)
-
吉川貴己、笹子三津留、佐野 武．胃癌治療の新しいエビデンスを求めて－臨床試験の取り組み－ JCOGでの取り組みと現状．外科治療 96(5): 953-958, 2007
-
吉川貴己、円谷 彰、長 晴彦．治癒を目指した胃がんの治療 ⑤術後補助化学療法．インフォームドコンセントのための図説シリーズ 胃がん、笹子三津留（編）、pp76-81、医薬ジャーナル、大阪/東京、2007
-
Noguchi Y, Fukuzawa K, Yoshikawa T, Younes RN. Surgical oncology: Role of videolaparocopy. In: Eubanks S, Cohen RV, Younes RN, and Brody F eds, Endosurgery for caner: Landes bioscience; 1-27, 1999.
-
Yoshikawa T, Motohashi H, Tsuburaya A, Kobayashi O, Sairenji M, Noguchi Y. New strategy for the treatment of advanced or recurrent gastric carcinoma: Neoadjuvant immunochemotherapy of FLPO regimen (5-FU, Leucovorin, CDDP, and OK-432). In: Nakajima T and Yamaguchi T, eds. Multimodality therapy for gastric cancer: Springer-Verlag Tokyo; 148-153, 1999.
